The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Four-year real-world outcomes of atezolizumab and bevacizumab in HCC
Julien Edeline, MD, PhD, Centre Eugene Marquis, Rennes, France, discusses four-year follow-up data from the CHIEF French cohort, a real-world prospective study of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. Despite a complex population with frequent portal hypertension and cirrhosis, survival remained durable. Some responders achieved curative-intent conversion through transplant, resection, or ablation. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
